Original Literature | Model OverView |
---|---|
Publication
Title
Modulation of Toll-interleukin 1 receptor mediated signaling.
Affiliation
Department of Immunology, Lerner Research Institute, Cleveland ClinicFoundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. lix@ccf.org
Abstract
Toll-like receptors (TLRs) belong to the Toll-interleukin 1 receptorsuperfamily, which is defined by a common intracellular Toll-IL-1 receptor (TIR)domain. A group of TIR domain containing adaptors (MyD88, TIRAP, TRIF and TRAM),are differentially recruited to the Toll-IL-1 receptors, contributing to thespecificity of signaling. The IL-1 mediated signaling pathway serves as a"prototype" for other family members. Genetic and biochemical studies revealthat IL-1R uses adaptor molecule MyD88 to mediate a very complex pathway,involving a cascade of kinases organized by multiple adapter molecules intosignaling complexes, leading to activation of the transcription factor NFkappaB.Several Toll-like receptors utilize variations of the "prototype" pathway byemploying different adaptor molecules. Double-stranded RNA triggered,TLR3-mediated signaling is independent of MyD88, IRAK4, and IRAK. The adaptermolecule TRIF is utilized by TLR3 to mediate the activation of NFkappaB andIRF3. LPS-induced, TLR4-mediated signaling employs multiple TIR-domaincontaining adaptors, MyD88/TIRAP to mediate NFkappaB activation, TRIF/TRAM forIRF3 activation. Recent studies have also begun to unravel how these pathwaysare negatively regulated. SIGIRR (also known as TIR8), a member of TIRsuperfamily that does not activate the transcription factors NFkappaB and IRF3,instead negatively modulates responses. Cells from SIGIRR-null mice showenhanced activation in response to either IL-1 or certain Toll ligands. Inaddition to SIGIRR, several other negative regulators have been shown to inhibitthe TIR signaling, including ST2, IRAKM, MyD88s, SOCS1, and Triad3A. Thecoordinated positive and negative regulation of the TIR signaling ensures theappropriate modulation of the innate and inflammatory responses.
PMID
15662540
|
Entity
Process
TRAF6
--
MO000000212
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m183
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000000212 |
--
IkappaB-alpha{p}: NFkappaB
--
MO000000220
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m190
10
infinite
0
TRANSPATH | MO000000220 |
--
IkappaB-alpha: NFkappaB
--
MO000000233
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m199
10
infinite
0
InterPro | IPR002110 |
TRANSPATH | MO000000233 |
--
TNF-alpha
--
MO000000289
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m230
10
infinite
0
InterPro | IPR003636 |
TRANSPATH | MO000000289 |
--
MyD88
--
MO000016573
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1572
10
infinite
0
InterPro | IPR000157 |
TRANSPATH | MO000016573 |
--
TLR4
--
MO000019394
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m3961
10
infinite
0
InterPro | IPR000157 |
TRANSPATH | MO000019394 |
--
dsRNA:TLR3:TRIF
--
MO000041437
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m19305
10
infinite
0
TRANSPATH | MO000041437 |
--
dsRNA:TLR3
--
MO000041446
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m19314
10
infinite
0
TRANSPATH | MO000041446 |
--
TLR9
--
MO000042012
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m19828
10
infinite
0
TRANSPATH | MO000042012 |
--
MyD88:MyD88
--
MO000050640
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m192928
10
infinite
0
TRANSPATH | MO000050640 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
e100
--
e100
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m103
0
infinite
0
--
csml-variable:Double
m104
0
infinite
0
--
TLR4:MyD88: TIRAP
--
e103
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m106
0
infinite
0
--
LPS:TLR4: TIRF
--
e104
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m107
0
infinite
0
--
LPS:TLR4: TIRF: TRAM
--
e105
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m108
0
infinite
0
--
IRF-3 {p}: IRF-3: p300 {nucleus}
--
e106
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m109
0
infinite
0
--
NF-kappaB [activated}
--
e11
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m11
10
infinite
0
InterPro | IPR008967 |
TRANSPATH | MO000100032 |
--
IkappaB-alpha{ub}: NFkappaB
--
e12
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m12
0
infinite
0
--
IkappaB-alpha {degraded}
--
e13
cso30:c:EntityBiological
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m13
0
infinite
0
--
NF-kappaB [nucleus}
--
e14
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m14
10
infinite
0
InterPro | IPR008967 |
TRANSPATH | MO000100032 |
--
IL-1: IL-1RI
--
e15
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m15
0
infinite
0
--
IL-1: IL-1RI: MyD88
--
e16
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m16
0
infinite
0
--
IL-1: IL-1RI: MyD88: IRAK: IRAK-4
--
e17
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
csml-variable:Double
m17
0
infinite
0
--
IL-1: IL-1RI: MyD88: IRAK {p}: IRAK-4: TRAF6
--
e18
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m18
0
infinite
0
--
IL-1: IL-1RI: MyD88: IRAK {p}: IRAK-4
--
e19
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m19
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
IL-1: IL-1RI: MyD88: IRAK [p}: IRAK-4: TRAF6: Pellino1
--
e20
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
csml-variable:Double
m20
0
infinite
0
--
IRAK {p}: IRAK-4: TRAF6: Pellino1
--
e21
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m21
0
infinite
0
--
IRAK {p}: TRAF6: TAK1: TAB1: TAB2
--
e22
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m22
0
infinite
0
--
IRAK {p}: TRAF6: TAK1 {p}: TAB1: TAB2 {p}
--
e23
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m23
0
infinite
0
--
IRAK-4: Pellino1
--
e24
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m24
0
infinite
0
--
IRAK {p}: TRAF6: TAK1 {p}: TAB1: TAB2 {p}
--
e25
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m25
0
infinite
0
--
IRAK {p}: TRAF6: TAK1 {p}{activated}: TAB1: TAB2 {p}
--
e26
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m26
0
infinite
0
--
MAPK6
--
e27
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m27
0
infinite
0
--
MAPK {activated}
--
e28
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m28
0
infinite
0
--
JNK {activated}
--
e29
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m30
10
infinite
0
TRANSPATH | MO000000023 |
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
IRAK {p}: TRAF6: TAK1 {p}: TAB1: TAB2 {p} : Ubc13: Uev1A
--
e33
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m34
0
infinite
0
--
Uev1A
--
e34
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m35
0
infinite
0
--
IRAK {p}: TRAF6 {ub}: TAK1 {p}: TAB1: TAB2 {p} : Ubc13: Uev1A
--
e35
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m36
0
infinite
0
--
MEKK3: TRAF6
--
e36
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m37
0
infinite
0
--
dsRNA:TLR3:TRIF:TRAF6:TAK1:TAB2
--
e37
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m38
10
infinite
0
TRANSPATH | MO000041496 |
--
dsRNA:TLR3:TRIF:TRAF6:TAK1:TAB2: RIP1
--
e38
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m40
0
infinite
0
--
NF-kappaB
--
e39
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m41
10
infinite
0
InterPro | IPR008967 |
TRANSPATH | MO000100032 |
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
IRF-3 {p}
--
e40
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m42
10
infinite
0
InterPro | IPR008984 |
TRANSPATH | MO000007694 |
--
csml-variable:Double
m43
0
infinite
0
--
TBK1: IKK-i {activated}
--
e42
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m44
0
infinite
0
--
MyD88: TIRAP: ST2
--
e44
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m46
0
infinite
0
--
IL-1: IL-1RI: MyD88: IRAK {p}: IRAK-4: TRAF6: SIGIRR
--
e45
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m47
0
infinite
0
--
IRAK-2d
--
e46
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m48
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000016566 |
--
IRAK-2c
--
e47
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m49
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000016566 |
--
IKK-alpha: IKK-beta: IKK-gamma
--
e5
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
IKK-alpha {p}: IKK-beta {p}: IKK-gamma
--
e6
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
IRAK-2c
--
e63
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m65
0
infinite
0
--
LPS: TLR4
--
e64
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m66
0
infinite
0
--
IL-1: IL-1RI: MyD88s
--
e66
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
csml-variable:Double
m68
0
infinite
0
--
MyD88s
--
e67
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m69
0
infinite
0
--
SOCS1
--
e68
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m70
0
infinite
0
--
NO2-
--
e69
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m71
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
csml-variable:Double
m73
0
infinite
0
--
P38 {p}
--
e71
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m74
0
infinite
0
--
TLR6: TLR2
--
e72
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m75
0
infinite
0
--
Uba: ubiquitin
--
e73
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m76
0
infinite
0
--
lipoprotein
--
e74
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m77
0
infinite
0
--
lipoprotein: TLR6: TLR2
--
e76
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m79
0
infinite
0
--
Ubc: ubiquitin
--
e77
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m80
0
infinite
0
--
fagellin
--
e78
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m81
0
infinite
0
--
TLR4{ub}
--
e79
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m82
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
IRF-3 {p}: IRF-3: p300
--
e81
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m84
0
infinite
0
--
Triad3A
--
e82
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m85
0
infinite
0
--
TLR9{ub}
--
e83
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m86
0
infinite
0
--
TLR9 {degraded}
--
e84
cso30:c:EntityBiological
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m87
0
infinite
0
--
TLR4 {degraded}
--
e85
cso30:c:EntityBiological
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m88
0
infinite
0
--
TRAF6: TAK1: TAB2
--
e86
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m89
0
infinite
0
--
TRAF6: TAK1 {p}: TAB2
--
e87
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m90
0
infinite
0
--
flagellin
--
e88
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m91
0
infinite
0
--
bacterial DNA
--
e89
cso30:c:Dna
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m92
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
bacterial DNA: TLR9
--
e90
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m93
0
infinite
0
--
R848
--
e91
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
csml-variable:Double
m94
0
infinite
0
--
R848: TLR7
--
e92
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m95
0
infinite
0
--
R848: TLR8
--
e93
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m96
0
infinite
0
--
ssRNA
--
e94
cso30:c:Rna
cso30:i:CC_Extracellular
--
csml-variable:Double
m97
0
infinite
0
--
ssRNA: TLR7
--
e95
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m98
0
infinite
0
--
ssRNA: TLR8
--
e96
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m99
0
infinite
0
--
IRF-3 {p}: IRF-3
--
e97
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m100
0
infinite
0
--
IRF-3 {p}: IRF-3: CBP
--
e98
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m101
0
infinite
0
--
IRF-3 {p}: IRF-3: CBP{nucleus}
--
e99
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m102
0
infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c186 : 1
stoichiometry:c2 : 1
m5*m90*0.1
nodelay
--
0
PMID: 15662540 Activation of the IKK complex involves the phosphorylation of two serine residues located in the activation loop within the kinase domain of IKK¦Á (S176 and S180) or IKK¦Â (S177 and S181). PMID: 15662540 Once activated, TAK1 can directly phosphorylate IKK¦Â and mitogen-activated protein kinase kinase 6. PMID: 15662540 TRAF6-TAK1-TAB2 are then translocated to the cytosol, where TAK1 is phosphorylated and activated, leading to the activation of IKK and NF¦ÊB.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c23 : 1
stoichiometry:c118 : 1
stoichiometry:c26 : 1
m17*0.1
nodelay
--
0
PMID: 15662540 During the formation of Complex I IRAK4 is activated, leading to the hyperphosphorylation of IRAK. PMID: 15662540 Unlike MyD88, MyD88s does not bind IRAK4, and overexpression of MyD88s does not induce IRAK phosphorylation.
p11
p11
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c28 : 1
stoichiometry:c29 : 1
stoichiometry:c30 : 1
m19287*m18*0.1
nodelay
--
0
PMID: 15662540, 12496252 During the formation of Complex I IRAK4 is activated, leading to the hyperphosphorylation of IRAK, which creates an interface for its interaction with adapter Pellino 1.
p12
p12
cso30:i:ME_Dissociation
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c31 : 1
stoichiometry:c98 : 1
stoichiometry:c32 : 1
stoichiometry:c33 : 1
m20*0.1
nodelay
--
0
PMID: 15662540 The formation of Pellino 1-IRAK4-IRAKTRAF6 causes conformational changes in the receptor complex (Complex I), releasing these signaling molecules from the receptor. PMID: 15662540 IRAKM prevents the dissociation of the IRAK-IRAK4 from MyD88 thereby inhibiting the formation of the IRAK-TRAF6 interaction.
p13
p13
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c34 : 1
stoichiometry:c35 : 1
stoichiometry:c36 : 1
stoichiometry:c37 : 1
stoichiometry:c38 : 1
stoichiometry:c41 : 1
m21*m1573*m1583*m6433*0.1
nodelay
--
0
PMID: 15662540 The released components then interact with the membrane-bound preassociated transforming growth factor ¦Â activated kinase (TAK) 1?transforming growth factor ¦Â activated protein kinase 1 binding protein (TAB) 1?TAB2 [28], resulting in the formation of Complex II (IRAK-TRAF6-TAK1-TAB1-TAB2).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c39 : 1
stoichiometry:c40 : 1
m22*0.1
nodelay
--
0
PMID: 15662540 TAK1 and TAB2 are phosphorylated in the membrane-bound Complex II.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c42 : 1
stoichiometry:c43 : 1
m23*0.1
nodelay
--
0
PMID: 15662540 TAK1 and TAB2 are phosphorylated in the membrane-bound Complex II, triggering the dissociation and translocation of TRAF6-TAK1-TAB1-TAB2 (Complex III) from the membrane to the cytosol.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c64 : 1
stoichiometry:c61 : 1
m36*0.1
nodelay
--
0
PMID: 15662540 The translocated Complex III interacts with additional factors in the cytosol, leading to TAK1 activation. PMID: 15662540 The activation of TAK1 eventually leads to the activation of IKK. PMID: 15662540 Furthermore, it was shown that the TAK1 complex (TAK1-TAB1-TAB2) is activated by association with ubiquitinated TRAF6.
p17
p17
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c65 : 1
stoichiometry:c66 : 1
stoichiometry:c67 : 1
m183*m1116*0.1
nodelay
--
0
PMID: 15662540 It has been shown that MEKK3 forms a complex with TRAF6 in response to IL-1 and is crucial for IL-1 induced NF¦ÊB activation.
p18
p18
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c51 : 1
stoichiometry:c50 : 1
stoichiometry:c52 : 1
m29*m28*0.1
nodelay
--
0
PMID: 15662540 Once activated, TAK1 can directly phosphorylate IKK¦Â and mitogen-activated protein kinase kinase 6, leading to the activation of both the c-Jun N-terminal kinase and NF¦ÊB signaling pathways.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c53 : 1
stoichiometry:c55 : 1
stoichiometry:c54 : 1
m31*m30*0.1
nodelay
--
0
PMID: 15662540 Activated TAK1 has also been implicated in the IL-1 induced activation of mitogen-activated protein kinase kinase 6 and c-Jun N-terminal kinase [46], leading to the activation of other transcription factors, including activating transcription factor and activator protein 1.
p2
p2
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c3 : 1
stoichiometry:c5 : 1
stoichiometry:c135 : 1
stoichiometry:c136 : 1
stoichiometry:c4 : 1
m199*m6*m66*0.1
nodelay
--
0
PMID: 15662540 The IKK¦Á and IKK¦Â subunits preferentially form heterodimers, and both can directly phosphorylate the critical S32 and S36 residues of I¦ÊB¦Á. PMID: 15662540 LPS-induced I¦ÊB and p38 phosphorylation are upregulated in SOCS1- deficient macrophages. Moreover, forced expression of SOCS1 suppresses LPS-induced NF¦ÊB activation.
p20
p20
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c56 : 1
stoichiometry:c58 : 1
stoichiometry:c57 : 1
m219*m30*0.1
nodelay
--
0
PMID: 15662540 Activated TAK1 has also been implicated in the IL-1 induced activation of mitogen-activated protein kinase kinase 6 and c-Jun N-terminal kinase [46], leading to the activation of other transcription factors, including activating transcription factor and activator protein 1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c45 : 1
stoichiometry:c44 : 1
stoichiometry:c62 : 1
stoichiometry:c59 : 1
m25*m6443*m35*0.1
nodelay
--
0
PMID: 15662540 TRAF6 functions as part of a unique E3 complex, with Ubc13 and Uev1A, and TRAF6 itself is the target of ubiquitination.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c60 : 1
stoichiometry:c63 : 1
m34*0.1
nodelay
--
0
PMID: 15662540 TRAF6 functions as part of a unique E3 complex, with Ubc13 and Uev1A, and TRAF6 itself is the target of ubiquitination.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c47 : 1
stoichiometry:c49 : 1
stoichiometry:c48 : 1
m27*m26*0.1
nodelay
--
0
PMID: 15662540 Once activated, TAK1 can directly phosphorylate IKK¦Â and mitogen-activated protein kinase kinase 6.
p24
p24
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c99 : 1
stoichiometry:c104 : 1
stoichiometry:c106 : 1
stoichiometry:c246 : 1
stoichiometry:c102 : 1
m41*m63*0.1
nodelay
--
0
PMID: 15662540 When over expressed, IRAK2a and IRAK2b potentiate NF¦ÊB activation by LPS. Interestingly, IRAK2c and IRAK2d were inhibitory.
p25
p25
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c68 : 1
stoichiometry:c69 : 1
stoichiometry:c70 : 1
m119368*m3965*0.1
nodelay
--
0
PMID: 15662540, 11607032 TLR3 recognizes doublestranded RNA (dsRNA).
p26
p26
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c71 : 1
stoichiometry:c75 : 1
stoichiometry:c72 : 1
m19314*m18998*0.1
nodelay
--
0
PMID: 15662540, 12872135, 12855817 TRIF was recently identified as an adapter for TLR3.
p27
p27
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c73 : 1
stoichiometry:c76 : 1
stoichiometry:c77 : 1
stoichiometry:c78 : 1
stoichiometry:c74 : 1
m19305*m183*m6433*m1573*0.1
nodelay
--
0
PMID: 15662540 adapter molecule TRIF recruits TRAF6?TAK1?TAB2 to TLR3 through its TRAF6-binding site.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c79 : 1
stoichiometry:c80 : 1
stoichiometry:c81 : 1
m38*m39*0.1
nodelay
--
0
PMID: 15662540 receptor interacting protein (RIP) 1 has also been implicated in TLR3/TRIFmediated NF¦ÊB activation.
p29
p29
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c82 : 1
stoichiometry:c84 : 1
stoichiometry:c107 : 1
stoichiometry:c243 : 1
stoichiometry:c83 : 1
m41*m40*0.1
nodelay
--
0
PMID: 15662540 it is possible that RIP1 directly cooperates with the TRAF6-containing complex, facilitating the NF¦ÊB activation process. PMID: 15662540 When over expressed, IRAK2a and IRAK2b potentiate NF¦ÊB activation by LPS. Interestingly, IRAK2c and IRAK2d were inhibitory.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c6 : 1
stoichiometry:c7 : 1
m190*0.1
nodelay
--
0
PMID: 15662540 Phospho-I¦ÊB is then recognized by the ¦Â-transducin repeat containing protein containing Skp1/Cullin/F-box ubiquitin ligase complex, leading to its ubiquitination and degradation by the proteasome.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c85 : 1
stoichiometry:c89 : 1
stoichiometry:c86 : 1
m43*m108*0.1
nodelay
--
0
PMID; 15662540 TRIF leads to the activation of TBK1/IKK¦Å, resulting in IRF3 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c205 : 1
stoichiometry:c206 : 1
m42*0.1
nodelay
--
0
PMID: 15662540 Viral infection and Toll ligands (dsRNA and LPS) lead to the phosphorylation of IRF3 and its subsequent dimerization.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c92 : 1
stoichiometry:c91 : 1
stoichiometry:c93 : 1
m41575*m18*0.1
nodelay
--
0
PMID:15662540, 12925853 The fact that SIGIRR forms a complex with the IL-1 receptor, IRAK, and TRAF6 upon IL-1 stimulation suggests that SIGIRR functions through its interaction with the TIR complex.
p33
p33
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c94 : 1
stoichiometry:c95 : 1
stoichiometry:c96 : 1
stoichiometry:c97 : 1
m1572*m6810*m22456*0.1
nodelay
--
0
PMID: 15662540 Overexpression of ST2 was found to inhibit NF¦ÊB activation because ST2 associated with, and probably sequestered, MyD88 and TIRAP.Overexpression of ST2 was found to inhibit NF¦ÊB activation because ST2 associated with, and probably sequestered, MyD88 and TIRAP.
p34
p34
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c100 : 1
stoichiometry:c103 : 1
stoichiometry:c105 : 1
stoichiometry:c247 : 1
stoichiometry:c101 : 1
m41*m64*0.1
nodelay
--
0
PMID: 15662540 When over expressed, IRAK2a and IRAK2b potentiate NF¦ÊB activation by LPS. Interestingly, IRAK2c and IRAK2d were inhibitory.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c108 : 1
stoichiometry:c109 : 1
m66*0.1
nodelay
--
0
PMID: 15662540 LPS induces the expression of IRAK2c.
p36
p36
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c110 : 1
stoichiometry:c111 : 1
stoichiometry:c112 : 1
m155666*m3961*0.1
nodelay
--
0
PMID: 15662540 LPS induces the expression of IRAK2c.
p37
p37
cso30:i:ME_Dimerization
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c17 : 1
stoichiometry:c113 : 1
m1572*0.1
nodelay
--
0
PMID: 15662540 MyD88 forms homodimers through DD-DD and TIR-TIR domain interactions and exists as a dimer when recruited to the receptor complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c115 : 1
stoichiometry:c46 : 1
stoichiometry:c117 : 1
m15*m1572*0.1
nodelay
--
0
PMID: 15662540 Unlike MyD88, MyD88s does not bind IRAK4, and overexpression of MyD88s does not induce IRAK phosphorylation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c119 : 1
stoichiometry:c120 : 1
m66*0.1
nodelay
--
0
PMID: 15662540 MyD88s is induced in monocytes upon LPS stimulation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c8 : 1
stoichiometry:c9 : 1
stoichiometry:c10 : 1
m12*0.1
nodelay
--
0
PMID: 15662540 Phospho-I¦ÊB is then recognized by the ¦Â-transducin repeat containing protein containing Skp1/Cullin/F-box ubiquitin ligase complex, leading to its ubiquitination and degradation by the proteasome.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c121 : 1
stoichiometry:c116 : 1
m69*0.1
nodelay
--
0
PMID: 15662540 MyD88s is induced in monocytes upon LPS stimulation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c123 : 1
stoichiometry:c124 : 1
m66*0.1
nodelay
--
0
PMID: 15662540 LPS induces the expression of SOCS1 in macrophages.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c125 : 1
stoichiometry:c126 : 1
m93501*0.1
nodelay
--
0
PMID: 15662540 LPS induces the expression of SOCS1 in macrophages.
p43
p43
cso30:i:ME_ChangeInMaterialConcentration
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c127 : 1
stoichiometry:c129 : 1
stoichiometry:c128 : 1
m66*0.1
nodelay
--
0
PMID: 15662540 LPS-induced NO2¡Ý synthesis and tumor necrosis factor ¦Á production are augmented in SOCS1- deficient macrophages.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c132 : 1
stoichiometry:c133 : 1
m93309*0.1
nodelay
--
0
PMID: 15662540 LPS-induced NO2¡Ý synthesis and tumor necrosis factor ¦Á production are augmented in SOCS1- deficient macrophages.
p45
p45
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c130 : 1
stoichiometry:c134 : 1
stoichiometry:c131 : 1
m66*0.1
nodelay
--
0
PMID: 15662540 LPS-induced NO2¡Ý synthesis and tumor necrosis factor ¦Á production are augmented in SOCS1- deficient macrophages.
p46
p46
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c137 : 1
stoichiometry:c139 : 1
stoichiometry:c140 : 1
stoichiometry:c138 : 1
m72*m66*0.1
nodelay
--
0
PMID: 15662540 LPS-induced I¦ÊB and p38 phosphorylation are upregulated in SOCS1- deficient macrophages.
p47
p47
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c143 : 1
stoichiometry:c144 : 1
stoichiometry:c146 : 1
m3964*m3987*0.1
nodelay
--
0
PMID: 15662540, 11095740 TLR6 associates with TLR2 and recognizes lipoproteins from microplasma.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c141 : 1
stoichiometry:c142 : 1
stoichiometry:c145 : 1
m73*m3556*0.1
nodelay
--
0
PMID: 15662540 In an initial step the ubiquitin-activating enzyme (E1 or Uba) forms a thioester bond with the C-terminus of ubiquitin.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c162 : 1
stoichiometry:c167 : 1
stoichiometry:c209 : 1
m4512*m100*0.1
nodelay
--
0
PMID: 15662540 Viral infection and Toll ligands (dsRNA and LPS) lead to the phosphorylation of IRF3 and its subsequent dimerization and interaction with the coactivaotors cAMP-response element binding protein binding protein and p300.
p5
p5
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c11 : 1
stoichiometry:c14 : 1
stoichiometry:c15 : 1
m185*m1589*0.1
nodelay
--
0
PMID: 15662540 The Ig domain subgroup includes IL-1 receptor (IL-1R) 1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c149 : 1
stoichiometry:c150 : 1
stoichiometry:c153 : 1
m75*m77*0.1
nodelay
--
0
PMID: 15662540, 11095740 TLR6 associates with TLR2 and recognizes lipoproteins from microplasma.
p51
p51
cso30:i:ME_Ubiquitination
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c157 : 1
stoichiometry:c158 : 1
stoichiometry:c161 : 1
stoichiometry:c160 : 1
stoichiometry:c178 : 1
m3961*m80*m83*0.1
nodelay
--
0
PMID:15662540 In the final step the E2 enzyme donates ubiquitin to a lysine residue of the target protein, either directly or with the assistance of ubiquitin protein ligase (E3 or Ubr).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c155 : 1
stoichiometry:c163 : 1
stoichiometry:c159 : 1
m3961*m85*0.1
nodelay
--
0
PMID: 15662540 Triad3A overexpression promoted substantial degradation of TLR4 and TLR9.
p53
p53
cso30:i:ME_Ubiquitination
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c164 : 1
stoichiometry:c165 : 1
stoichiometry:c169 : 1
stoichiometry:c170 : 1
stoichiometry:c177 : 1
m80*m83*m19828*0.1
nodelay
--
0
PMID:15662540 In the final step the E2 enzyme donates ubiquitin to a lysine residue of the target protein, either directly or with the assistance of ubiquitin protein ligase (E3 or Ubr).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c168 : 1
stoichiometry:c171 : 1
stoichiometry:c172 : 1
m85*m19828*0.1
nodelay
--
0
PMID: 15662540 Triad3A overexpression promoted substantial degradation of TLR4 and TLR9.
p55
p55
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c173 : 1
stoichiometry:c174 : 1
m86*0.1
nodelay
--
0
PMID: 15662540 Triad3A overexpression promoted substantial degradation of TLR4 and TLR9.
p56
p56
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c175 : 1
stoichiometry:c176 : 1
m82*0.1
nodelay
--
0
PMID: 15662540 Triad3A overexpression promoted substantial degradation of TLR4 and TLR9.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c181 : 1
stoichiometry:c182 : 1
stoichiometry:c183 : 1
m38*0.1
nodelay
--
0
PMID: 15662540 TRAF6-TAK1-TAB2 are then translocated to the cytosol.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c184 : 1
stoichiometry:c185 : 1
m89*0.1
nodelay
--
0
PMID: 15662540 TRAF6-TAK1-TAB2 are then translocated to the cytosol, where TAK1 is phosphorylated and activated.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c12 : 1
stoichiometry:c13 : 1
m11*0.1
nodelay
--
0
PMID: 15662540, 10837071, 10713156 The destruction of I¦ÊB unmasks the nuclear localization signal of NF¦ÊB, leading to its nuclear translocation and binding to the promoters of target genes.
p60
p60
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c154 : 1
stoichiometry:c156 : 1
stoichiometry:c166 : 1
m3966*m81*0.1
nodelay
--
0
PMID: 15662540, 11323673 While TLR5 mediates the induction of the immune response by bacterial flagellins.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c179 : 1
stoichiometry:c180 : 1
stoichiometry:c189 : 1
m19828*m92*0.1
nodelay
--
0
PMID: 15662540, 11130078 TLR9 has been shown to recognize bacterial DNA.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c190 : 1
stoichiometry:c191 : 1
stoichiometry:c192 : 1
m19940*m94*0.1
nodelay
--
0
PMID: 15662540, 11812998, 10346978 While a synthetic compound (imidazoquinoline compound R848) with antiviral activity has been described as a ligand for TLR7 and TLR8.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c193 : 1
stoichiometry:c194 : 1
stoichiometry:c195 : 1
m94*m19823*0.1
nodelay
--
0
11812998, 10346978 While a synthetic compound (imidazoquinoline compound R848) with antiviral activity has been described as a ligand for TLR7 and TLR8.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c196 : 1
stoichiometry:c197 : 1
stoichiometry:c198 : 1
m97*m19940*0.1
nodelay
--
0
PMID: 15662540, 14976261, 14976262, 15034168 recent studies showed that ssRNA is the natural ligand for TLR7/8.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c199 : 1
stoichiometry:c200 : 1
stoichiometry:c201 : 1
m97*m19823*0.1
nodelay
--
0
PMID: 15662540, 14976261, 14976262, 15034168 recent studies showed that ssRNA is the natural ligand for TLR7/8.
p66
p66
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c202 : 1
stoichiometry:c204 : 1
stoichiometry:c244 : 1
stoichiometry:c245 : 1
stoichiometry:c203 : 1
m41*m37*0.1
nodelay
--
0
PMID: 15662540 It has been shown that MEKK3 forms a complex with TRAF6 in response to IL-1 and is crucial for IL-1 induced NF¦ÊB activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c87 : 1
stoichiometry:c88 : 1
stoichiometry:c90 : 1
m44*m45*0.1
nodelay
--
0
PMID; 15662540 TRIF leads to the activation of TBK1/IKK¦Å, resulting in IRF3 activation. PMID: 15662540 Viral infection and Toll ligands (dsRNA and LPS) lead to the phosphorylation of IRF3 and its subsequent dimerization.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c207 : 1
stoichiometry:c208 : 1
stoichiometry:c210 : 1
m100*m2282*0.1
nodelay
--
0
PMID: 15662540 Viral infection and Toll ligands (dsRNA and LPS) lead to the phosphorylation of IRF3 and its subsequent dimerization and interaction with the coactivaotors cAMP-response element binding protein binding protein and p300.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c211 : 1
stoichiometry:c212 : 1
m101*0.1
nodelay
--
0
PMID: 15662540 The IRF3 complex then translocates to the nucleus.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c16 : 1
stoichiometry:c114 : 1
stoichiometry:c18 : 1
m15*m192928*0.1
nodelay
--
0
PMID: 15662540 Upon IL-1 stimulation adapter molecule MyD88 is first recruited to the IL-1 receptor.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c214 : 1
stoichiometry:c213 : 1
m102*0.1
nodelay
--
0
PMID: 15662540 The IRF3 complex then translocates to the nucleus, where it activates promoters containing IRF-binding sites.
p71
p71
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c216 : 1
stoichiometry:c217 : 1
stoichiometry:c218 : 1
m1572*m66*0.1
nodelay
--
0
PMID: 15662540, 10435584 TLR4-mediated NF¦ÊB activation was greatly reduced in MyD88- deficient mice, indicating the requirement of MyD88 for TLR4 signaling.
p72
p72
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c219 : 1
stoichiometry:c220 : 1
stoichiometry:c221 : 1
m6810*m105*0.1
nodelay
--
0
PMID: 15662540, 12447442, 12447441 Interestingly, TIRAP-deficient mice showed defects in activation of the MyD88-dependent signaling pathway through TLR4, but not IL-1R, indicating specificity of the TLR4-mediated MyD88-dependent pathway.
p73
p73
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c222 : 1
stoichiometry:c224 : 1
stoichiometry:c242 : 1
stoichiometry:c248 : 1
stoichiometry:c223 : 1
m41*m106*0.1
nodelay
--
0
PMID: 15662540 LPS-induced, TLR4-mediated signaling employs multiple TIR-domain containing adaptors, MyD88/TIRAP to mediate NF¦ÊB activation.
p74
p74
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c225 : 1
stoichiometry:c226 : 1
stoichiometry:c227 : 1
m18998*m66*0.1
nodelay
--
0
PMID: 15662540, 12855817 Such TLR4-mediated MyD88-independent activities were abolished in TRIF-deficient mice.
p75
p75
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c228 : 1
stoichiometry:c229 : 1
stoichiometry:c230 : 1
m107*m19005*0.1
nodelay
--
0
PMID: 15662540 TLR4- but not TLR3-mediated MyD88-independent IRF3 activation and interferon ¦Â production was abolished in TRAM-deficient mice.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c232 : 1
stoichiometry:c231 : 1
m108*0.1
nodelay
--
0
PMID: 15662540 LPS still stimulates the expression of certain genes, including interferon ¦Â, in MyD88- deficient mice.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c233 : 1
stoichiometry:c215 : 1
stoichiometry:c234 : 1
m45*m104*0.1
nodelay
--
0
PMID: 15662540 Recently the IKK-related kinases IKK¦Å and TRAF family member associated NF¦ÊB activator binding kinase binding kinase 1 have been implicated in the phosphorylation and activation of IRF3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c235 : 1
stoichiometry:c237 : 1
stoichiometry:c236 : 1
m45*m108*0.1
nodelay
--
0
PMID: 15662540 LPS-induced, TLR4-mediated signaling employs multiple TIR-domain containing adaptors, MyD88/TIRAP to mediate NF¦ÊB activation, TRIF/TRAM for IRF3 activation.
p79
p79
cso30:i:ME_Transference
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c147 : 1
stoichiometry:c148 : 1
stoichiometry:c151 : 1
stoichiometry:c152 : 1
m76*m78*0.1
nodelay
--
0
PMID: 15662540 In an initial step the ubiquitin-activating enzyme (E1 or Uba) forms a thioester bond with the C-terminus of ubiquitin, which is then transferred to a specific cysteine residue of an ubiquitinconjugating enzyme (E2 or Ubc).
p8
p8
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c19 : 1
stoichiometry:c20 : 1
stoichiometry:c21 : 1
stoichiometry:c22 : 1
m184*m17258*m16*0.1
nodelay
--
0
PMID: 15662540, 11960013, 8599092 Upon IL-1 stimulation adapter molecule MyD88 is first recruited to the IL-1 receptor, followed by the recruitment of two serine-threonine kinases, IRAK4 and IRAK.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c238 : 1
stoichiometry:c239 : 1
m109*0.1
nodelay
--
0
PMID: 15662540 The IRF3 complex then translocates to the nucleus, where it activates promoters containing IRF-binding sites.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c240 : 1
stoichiometry:c241 : 1
m84*0.1
nodelay
--
0
PMID: 15662540 The IRF3 complex then translocates to the nucleus.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c249 : 1
stoichiometry:c251 : 1
stoichiometry:c250 : 1
m5*m26*0.1
nodelay
--
0
PMID: 15662540 Activation of the IKK complex involves the phosphorylation of two serine residues located in the activation loop within the kinase domain of IKK¦Á (S176 and S180) or IKK¦Â (S177 and S181). PMID: 15662540 Once activated, TAK1 can directly phosphorylate IKK¦Â and mitogen-activated protein kinase kinase 6. PMID: 15662540 TRAF6-TAK1-TAB2 are then translocated to the cytosol, where TAK1 is phosphorylated and activated, leading to the activation of IKK and NF¦ÊB.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c24 : 1
stoichiometry:c27 : 1
stoichiometry:c25 : 1
m183*m19*0.1
nodelay
--
0
PMID: 15662540, 8837778 Upon IL-1 stimulation adapter molecule MyD88 is first recruited to the IL-1 receptor, followed by the recruitment of two serine-threonine kinases, IRAK4 and IRAK and the adapter TNF receptor associated factor (TRAF) 6.
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--